




RealRate

PHARMACEUTICAL 2022

Acurx Pharmaceuticals Inc
Rank 219 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Acurx Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acurx Pharmaceuticals Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 304% points. The greatest weakness of Acurx Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 29% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	844
Liabilities, Non-Current	0
Other Assets	13,254
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	67
Other Revenues	0
Property and Equipment	0
Research and Development	2,030
Selling, General and Administrative Expense	10,784

Output Variable	Value in 1000 USD
Assets	13,254
Liabilities	844
Expenses	12,814
Revenues	0
Stockholders Equity	12,410
Net Income	-12,748
Comprehensive Net Income	-12,748
BaseVar	13,489
ECR before LimitedLiability	203%
Economic Capital Ratio	304%